Harry R Dalton

Title: Innovations of Harry R Dalton

Introduction

Harry R Dalton is a notable inventor based in Bodmin, GB. He has made significant contributions to the field of virology, particularly in the study of hepatitis E virus (HEV). With a total of two patents to his name, Dalton's work has implications for vaccine development and cell culture technologies.

Latest Patents

Dalton's latest patents focus on the infectious hepatitis E virus genotype 3 recombinants. The invention relates to the discovery of an HEV strain from a chronically infected patient. This strain grows unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus. The invention also involves the identification of a new strain of HEV genotype 3 virus. Strain Kernow-C1 (genotype 3) of HEV, isolated from a chronically infected patient, was used to identify human, pig, and deer cell lines permissive for infection. The adaptation of the Kernow-C1 strain to growth in human hepatoma cells selected for a rare virus recombinant that contained an insertion of 174 ribonucleotides (58 amino acids) of a human ribosomal protein gene and additional mutations.

Career Highlights

Throughout his career, Dalton has worked with prestigious organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the Royal Cornwall Hospital Trust. His work in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Dalton has collaborated with notable coworkers, including Suzanne U Emerson and Priyanka Shukla. These collaborations have enriched his research and expanded the impact of his inventions.

Conclusion

Harry R Dalton's innovative work in the field of hepatitis E virus research showcases his dedication to advancing medical science. His patents and collaborations highlight the importance of teamwork in achieving significant breakthroughs.